Payment overview · 2025
General Payments
$3,825.91
91 reported records · 19 companies
Healthcare provider profile · identity verified
Kevin Patrick Kenney, MD
Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery · GAINESVILLE, FL · NPI 1740741651
Verified facts
What the public records show
CMS Open Payments records show Kevin Patrick Kenney, MD received $3,825.91 in general payments during 2025 across 91 reported records.
CVRx, Inc. accounted for 13.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| CVRx, Inc. | Unresolved — no canonical attribution shown | $530.72 | 13.9% | 9 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $487.69 | 12.8% | 5 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $411.44 | 10.8% | 10 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $351.04 | 9.2% | 22 | 2025 |
| Neuros Medical, Inc. | Unresolved — no canonical attribution shown | $328.18 | 8.6% | 10 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$313.88 | 8.2% | 4 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $308.79 | 8.1% | 5 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $261.82 | 6.8% | 10 | 2025 |
| InspireMD Ltd | Unresolved — no canonical attribution shown | $144.16 | 3.8% | 1 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $141.01 | 3.7% | 1 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $129.12 | 3.4% | 2 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $124.68 | 3.3% | 1 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $102.87 | 2.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $52.03 | 1.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $44.16 | 1.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.69 | 0.8% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $25.71 | 0.7% | 1 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $25.29 | 0.7% | 1 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $14.63 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,825.91 | 91 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $530.72 | 9 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $351.04 | 22 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $341.14 | 3 | 2025 |
Source payment records
|
|||||
| Altius Normalized: altius |
Device | Neuros Medical, Inc. | $328.18 | 10 | 2025 |
Source payment records
|
|||||
| ENROUTE Transcarotid Neuroprotection System Normalized: enroute transcarotid neuroprotection system |
Device | Boston Scientific Corporation | $234.63 | 7 | 2025 |
Source payment records
|
|||||
| AFX2 Bifurcated Endograft System Normalized: afx2 bifurcated endograft system |
Device | Endologix LLC | $194.94 | 3 | 2025 |
Source payment records
|
|||||
| LIMFLOW SYSTEM Normalized: limflow system |
Device | Stryker Corporation | $181.47 | 2 | 2025 |
Source payment records
|
|||||
| Penumbra System Normalized: penumbra system |
Device | Penumbra, Inc. | $146.55 | 2 | 2025 |
Source payment records
|
|||||
| CGuard Prime Carotid Stent System Normalized: cguard prime carotid stent system |
Device | InspireMD Ltd | $144.16 | 1 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $141.01 | 1 | 2025 |
Source payment records
|
|||||
| ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter Normalized: enroute enflate transcarotid rx balloon dilatation catheter |
Device | Boston Scientific Corporation | $134.40 | 1 | 2025 |
Source payment records
|
|||||
| CATALYFT PL EXPANDABLE INTERBODY SYSTEM Normalized: catalyft pl expandable interbody system |
Device | Medtronic, Inc. | $130.83 | 1 | 2025 |
Source payment records
|
|||||
| APLIGRAF Normalized: apligraf |
Device | Organogenesis Inc. | $129.12 | 2 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Bard Peripheral Vascular, Inc. | $124.68 | 1 | 2025 |
Source payment records
|
|||||
| AFFINITY Normalized: affinity |
Medical Supply | Organogenesis Inc. | $112.10 | 1 | 2025 |
Source payment records
|
|||||
| PURAPLY WOUND MATRIX Normalized: puraply wound matrix |
Device | Organogenesis Inc. | $112.10 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc. | $102.87 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc. | $102.87 | 1 | 2025 |
Source payment records
|
|||||
| PROTEGE RX Normalized: protege rx |
Device | Medtronic, Inc. | $82.44 | 1 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $80.35 | 8 | 2025 |
Source payment records
|
|||||
| ENDURANT IIS Normalized: endurant iis |
Device | Medtronic, Inc. | $75.72 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $52.03 | 3 | 2025 |
Source payment records
|
|||||
| Varithena Administration Pack Normalized: varithena administration pack |
Device | Boston Scientific Corporation | $42.41 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $28.69 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $26.96 | 1 | 2025 |
Source payment records
|
|||||
| Alto Abdominal Stent Graft System Normalized: alto abdominal stent graft system |
Device | Endologix LLC | $26.46 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $25.71 | 1 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL Normalized: mynx control |
Device | CORDIS US CORP. | $25.29 | 1 | 2025 |
Source payment records
|
|||||
| PIVOX OBLIQUE LATERAL SPINAL SYSTEM Normalized: pivox oblique lateral spinal system |
Device | Medtronic, Inc. | $24.89 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.20 | 1 | 2025 |
Source payment records
|
|||||
| Acticor 7 VR-T DX Normalized: acticor 7 vr t dx |
Device | BIOTRONIK INC. | $14.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Cilostazol | Cilostazol | 36 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 34 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 19 | 12 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,825.91 · 91 records | CVRx, Inc. | AFFINITY, AFX2 Bifurcated Endograft System, APLIGRAF, ARTIX MT, AURYON LASER SYSTEM 100-120 VAC, Acticor 7 VR-T DX, Altius, Alto Abdominal Stent Graft System, Assure WCD, Barostim Neo System, CATALYFT PL EXPANDABLE INTERBODY SYSTEM, CGuard Prime Carotid Stent System, CT THROMBECTOMY SYSTEM KIT, ELIQUIS, ENDURANT IIS, ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter, ENROUTE Transcarotid Neuroprotection System, FLOWTRIEVER CATHETER, S, Indigo System, LEQVIO, LIMFLOW SYSTEM, MYNX CONTROL, PIVOX OBLIQUE LATERAL SPINAL SYSTEM, PROTEGE RX, PURAPLY WOUND MATRIX, Penumbra System, REPATHA, RotarexS 6 F x 135 cm, VERQUVO, VYNDAQEL, Varithena Administration Pack | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error